Major drug companies continually research and develop new medications and treatments, which must be shown to be safe and effective before doctors can prescribe them to patients. Through lung cancerclinical trials, researchers test the effects of new drugs on a group of volunteers with lung cancer. Following a strict protocol and using carefully controlled conditions, researchers evaluate the investigational drugs under development and measure the ability of the new drug to treat lung cancer, its safety, and any possible side effects.
Some patients with lung cancer are reluctant to take part in clinical trials for fear of getting no treatment at all for their lungcancer. This is simply not true. Patients with lung cancer who participate in lung cancer clinical trials receive the most effective therapy currently available for the lung cancer -- or they may receive lung cancer treatments that are being evaluated for future use. These lung cancer drugs may be even more effective than the current lung cancer treatment. The only way to determine if a newer treatment is better than the currently available treatment is by clinical trial participation.
Diagnosis and Prognostic Factors
Prognosis in malignant mesothelioma is difficult to assess consistently because there is great variability in the time before diagnosis and the rate of disease progression. In large retrospective series of pleural mesothelioma patients, important prognostic factors were found to be:[1,2][Level of evidence: 3iiiA]
Prognostic Scoring Systems
Two prognostic scoring systems have been developed for...
This web site, developed by the nonprofit Coalition of Cancer Cooperative Groups, is the leading cancer clinical trial search engine. It is an unbiased cancer clinical trial matching and navigation service that enables patients to search for cancer trials based on disease and location.